• About
  • Masthead
  • License Content
  • Advertise
  • Submit Press Release
  • RSS/Email List
  • Write for us
  • Contact us
2 Minute Medicine
No Result
View All Result

No products in the cart.

SUBSCRIBE
  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • AccountLog-in/out
    • Subscribe
    • Sign-in
    • My account
2 Minute Medicine
  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • AccountLog-in/out
    • Subscribe
    • Sign-in
    • My account
SUBSCRIBE
2 Minute Medicine
Subscribe
Home All Specialties Chronic Disease

Olanzapine discontinuation leads to higher relapse in depression with psychosis

byDaniel Fisher
August 21, 2019
in Chronic Disease, Psychiatry
Reading Time: 3 mins read
1
Share on FacebookShare on Twitter

1.  In this randomized controlled trial, patients with Major depressive disorder with psychotic features who were stable on olanzapine and sertraline showed higher relapse upon discontinuation of olanzapine than those who remained on both drugs over 36 weeks.

2. Patients who remained on both drugs had more weight gain but no significant differences in metabolic markers.

Evidence Rating Level: 1 (Excellent)

Study Rundown: Major depressive disorder with psychotic features (MDD-p) is a debilitating form of depression typified by delusions and/or hallucinations that are generally treated with combination antidepressant and antipsychotic therapy. However, once a patient is stable, it is unclear if remaining on the antipsychotic is necessary to prevent relapse. In this randomized controlled trial, patients with MDD-p who were stable on olanzapine and sertraline showed higher relapse upon discontinuation of olanzapine than those who remained on both drugs over 36 weeks. While remaining on olanzapine increased the risk of weight gain, changes in other metabolic markers including LDL, HDL, and HbA1c were unaltered. Rates of parkinsonism but not akathisia were also higher in the continuation group.

The difference in relapse rates between groups was high and suggests a clear benefit of remaining on dual therapy even when stabilized. However, the risks of weight gain and extrapyramidal symptoms are important trade-offs that should be discussed with patients, and longer durations on olanzapine may eventually lead to metabolic marker abnormalities not captured by this relatively short study period. In addition, future studies determining an optimal window for withdrawal of antipsychotics and optimal tapering protocols would enhance these results.

Click to read the study in JAMA

Relevant Reading:Night-time home versus ambulatory blood pressure in determining target organ damage.

RELATED REPORTS

An implantable system overcomes orthostatic hypotension in a patient with multiple-system atrophy

Majority of long-acting injectable and oral antipsychotics are similar in efficacy for schizophrenia maintenance therapy

Vitamin D supplementation does not improve mental outcomes in adults with early psychosis

In-Depth [randomized controlled trial]: The Study of the Pharmacotherapy of Psychotic Depression-II (STOP-PD-II) recruited 126 adult patients with MDD-p who were stable for 8 weeks on dual sertraline (150-200 mg) and olanzapine (15-20mg) therapy to be randomized to discontinue or continue olanzapine for 36 weeks over 4 medical centers. Included patients had a MDD-p diagnosis and a Hamilton Depression Rating Scale score of >21 and a score of >2 on the Schedule for Affective Disorders and Schizophrenia as well as >1 score on the Delusion Assessment Scale. Excluded patients had another psychotic disorder, bipolar disorder, or intellectual disability, body-dysmorphic or obsessive compulsive disorders, dementia, significant substance abuse, neurologic disease affecting motor ability, type 1 diabetes, unstable physical illness. To be included, patients must have been at least in near remission for 12 weeks plus an 8 week stabilization period. The risk of relapse was higher with discontinuation of olanzapine (Hazard Ratio 0.25; CI95 0.13 to 0.48), representing a number needed to treat of 2.8 and was significant when controlling for age, remission versus near remission, and study site. Continuation of olanzapine was associated with significant daily rate of increased weight gain (0.13 lb; CI95 0.11 to 0.15), waist circumference (0.009 inches; CI95 0.004 to 0.014), and total cholesterol (0.29mg/dL; CI95 0.13 to 0.45) but not LDL (0.04mg/dL; CI95 −0.01 to 0.10), HDL (−0.01mg/dL; CI95 −0.03 to 0.01), triglycerides (−0.153mg/dL; CL95 −0.306 to 0.004), glucose (−0.02mg/dL;CI95 −0.12 to 0.08), or HbA1c levels (−0.0002mg/dL; CI95 −0.0021 to 0.0016). Rates of parkinsonism scores on the Simpson-Angus Scale were higher with continuation (p = 0.009) but not rates of akathisia (4.7% vs 4.8%).

Image: PD

©2019 2 Minute Medicine, Inc. All rights reserved. No works may be reproduced without expressed written consent from 2 Minute Medicine, Inc. Inquire about licensing here. No article should be construed as medical advice and is not intended as such by the authors or by 2 Minute Medicine, Inc.

Tags: major depressive disorder (MDD)OlanzapineparkinsonismPsychosissertraline
Previous Post

#VisualAbstract: Effect of Flexible Family Visitation on Delirium Among Patients in the Intensive Care Unit

Next Post

Quick Take: Assessment of long-term distant recurrence-free survival associated with tamoxifen therapy in post-menopausal patients with luminal A or luminal B breast cancer

RelatedReports

Increased number of daily steps linked with decreased mortality in older women
Cardiology

An implantable system overcomes orthostatic hypotension in a patient with multiple-system atrophy

May 10, 2022
Quick Take: Effect of Pregabalin on Radiotherapy-Related Neuropathic Pain in Patients With Head and Neck Cancer: A Randomized Controlled Trial
Chronic Disease

Majority of long-acting injectable and oral antipsychotics are similar in efficacy for schizophrenia maintenance therapy

March 15, 2022
Multiple opioid prescriptions associated with higher hospital admissions
Psychiatry

Vitamin D supplementation does not improve mental outcomes in adults with early psychosis

February 22, 2022
Provision of medically-tailored meals linked with lower admissions and medical spending
Wellness

Wellness Check: Nutrition

February 17, 2022
Next Post
Age and breast cancer risk factors associated with false-positive mammography results

Quick Take: Assessment of long-term distant recurrence-free survival associated with tamoxifen therapy in post-menopausal patients with luminal A or luminal B breast cancer

Quick Take: Intravenous patient-controlled analgesia versus thoracic epidural analgesia after open liver surgery

Quick Take: Intravenous patient-controlled analgesia versus thoracic epidural analgesia after open liver surgery

Maternal vaccination during pregnancy not associated with infant hospitalization, mortality

Quick Take: Association between maternal pre-pregnancy obesity and preterm birth according to maternal age and race or ethnicity

Please login to join discussion

License Our Award-Winning Physician-Written Medical News and Visual Abstracts

2 Minute Medicine is the leading authoritative medical news licensing service, and the only with reports written by practicing doctors.

LICENSE CONTENT

2MM+ Premium Access

No ads & unlimited access to all current reports, over 9000 searchable archived reports, visual abstracts, Weekly Rewinds, and the online edition of The Classics Series™ textbook.

Subscription Options
2 Minute Medicine

2 Minute Medicine® is an award winning, physician-run, expert medical media company. Our content is curated, written and edited by practicing health professionals who have clinical and scientific expertise in their field of reporting. Our editorial management team is comprised of highly-trained MD physicians. Join numerous brands, companies, and hospitals who trust our licensed content.

Recent Reports

  • Vitamin and mineral supplementation associated with minimal to no benefit in the primary preventing of cardiovascular disease and cancer – US Preventative Services Task Force
  • RSVpreF vaccine prevents symptomatic respiratory syncytial virus infection
  • Incidence of Kawasaki disease found to be lower during the COVID-19 pandemic in the United States
License Content
Terms of Use | Disclaimer
Cookie Policy
Privacy Statement (EU)
Disclaimer

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.

  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.